Vecuronium Bromide
FDA-approved product (injectable, injection), marketed as Norcuron, Vecuronium Bromide.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Vecuronium Bromide. Its therapeutic class is shown instead.
- WHO therapeutic group
- Other quaternary ammonium compounds
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vecuronium Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery
NCT04002128 · start 2008-01
Registered record
- Registry ID
- NCT04002128
- Conditions
- Colorectal Neoplasms Malignant; Surgical Procedures, Operative; Stomach Neoplasms; Pancreatic Cancer, Adult
- Interventions
- Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2012-03
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal Neoplasms Malignant; Surgical Procedures, Operative; Stomach Neoplasms; Pancreatic Cancer, AdultInterventionTracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.PhaseNot applicableRegistry statusCompletedA Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)
NCT00591786 · start 2005-12-05
Registered record
- Registry ID
- NCT00591786
- Conditions
- Anesthesia, General
- Interventions
- Sugammadex
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-12-05
- Completion
- 2006-10-19
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnesthesia, GeneralInterventionSugammadexPhasePhase 2Registry statusCompletedComparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)
NCT00451217 · start 2005-11-17
Registered record
- Registry ID
- NCT00451217
- Conditions
- Anesthesia, General
- Interventions
- Sugammadex; Neostigmine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-11-17
- Completion
- 2006-03-06
- Enrolment
- 198
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnesthesia, GeneralInterventionSugammadex; NeostigminePhasePhase 3Registry statusCompletedA Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
NCT00552929 · start 2005-10-04
Registered record
- Registry ID
- NCT00552929
- Conditions
- Anesthesia, General
- Interventions
- Sugammadex
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-10-04
- Completion
- 2006-09-15
- Enrolment
- 102
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnesthesia, GeneralInterventionSugammadexPhasePhase 2Registry statusCompletedComparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)
NCT00970762 · start 2003-02
Registered record
- Registry ID
- NCT00970762
- Conditions
- Anesthesia
- Interventions
- Rocuronium 0.6 mg/kg intubating dose; Rocuronium 0.9 mg/kg intubating dose; Rocuronium 0.1 mg/kg maintenance dose; Rocuronium 0.15 mg/kg maintenance dose; Rocuronium 0.2 mg/kg maintenance; Vecuronium 0.1 mg/kg intubating dose; Vecuronium 0.025 mg/kg maintenance dose
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-02
- Completion
- 2004-02
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnesthesiaInterventionRocuronium 0.6 mg/kg intubating dose; Rocuronium 0.9 mg/kg intubating dose; Rocuronium 0.1 mg/kg maintenance dose; Rocuronium 0.15 mg/kg maintenance dose +3 morePhasePhase 3Registry statusCompleted